Money in the placement came through the sale of 7,000 shares of Series F convertible preferred stock at $1,000 per share. Funds will be supplied through in initial tranche of $3.5 million and a second tranche, which is subject to shareholder approval and a resale registration statement for the remaining amount.
Funds from the round will be used to support the continued commercialization of the company’s Quell over-the-counter wearable pain relief device in the US, as well as for general working capital purposes.
Series F convertible stock in the round are convertible at any time into an aggregate of approximately 2.7 million shares of common stock at a price of $2.63 per share, Waltham, Mass.-based NeuroMetrix said. The company will need to seek shareholder approval for the 2nd tranche of Series F shares.
The 1st tranche in the offering is expected to close on or about July 13, according to a press release.
In May, NeuroMetrix said it would engage in a 1-for-8 reverse stock split as it looks to satisfy the $1 minimum bid price requirement for the NASDAQ capital market.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.